Treatment of Persistent Tardive Dyskinesia

Initial Management Steps

• For patients with moderate to severe or disabling persistent tardive dyskinesia, the American Psychiatric Association recommends treating with a VMAT2 inhibitor (valbenazine or deutetrabenazine) as first-line pharmacotherapy 1, 2
• If clinically feasible, gradually withdraw the offending antipsychotic medication, as this remains the primary intervention when the underlying psychiatric condition allows, according to Praxis Medical Insights 2, 3

Pharmacological Treatment for Persistent TD

• The American Psychiatric Association recommends using VMAT2 inhibitors as first-line treatment, with valbenazine and deutetrabenazine demonstrating robust efficacy 1, 2

Critical Pitfalls to Avoid

• Anticholinergic medications (benztropine, trihexyphenidyl) are contraindicated for tardive dyskinesia and may actually worsen the condition, as stated by the American Psychiatric Association and Praxis Medical Insights 1, 2, 4
• In elderly patients on typical antipsychotics, specifically avoid benztropine or trihexyphenidyl when extrapyramidal symptoms occur, according to Praxis Medical Insights 4

Alternative Antipsychotic Options

• Clozapine is the preferred switch option if continued antipsychotic therapy is necessary, given its lowest risk profile for movement disorders, as recommended by Praxis Medical Insights 2

Monitoring and Follow-Up

• Use the Abnormal Involuntary Movement Scale (AIMS) to monitor treatment response, with regular assessments at least every 3-6 months, as suggested by Praxis Medical Insights 2

Evidence Quality Considerations

• The recommendation for VMAT2 inhibitors is based on Level 1A evidence from the American Psychiatric Association guidelines, supported by FDA approval based on randomized controlled trials 1